484 results on '"Kapłon-Cieślicka A"'
Search Results
2. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
- Author
-
Maciej Banach, Stanisław Surma, Agnieszka Kapłon-Cieślicka, Przemysław Mitkowski, Grzegorz Dzida, Tomasz Tomasik, and Agnieszka Mastalerz-Migas
- Subjects
lipid disorders ,lipid lowering therapy ,therapy personalisation ,pitavastatin ,statin intolerance ,Medicine - Abstract
Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients’ fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders.
- Published
- 2023
- Full Text
- View/download PDF
3. Safety and efficacy of percutaneous atrial appendage closure followed by antiplatelet therapy in a high-risk population: single-center experience with a WATCHMAN device
- Author
-
Jakub Maksym, Agnieszka Kapłon-Cieślicka, Piotr Scisło, Zenon Huczek, Michał Marchel, Radosław Piątkowski, Janusz Kochman, Grzegorz Opolski, Marcin Grabowski, and Tomasz Mazurek
- Subjects
antiplatelet therapy ,atrial fibrillation ,stroke prevention ,left atrial appendage closure ,Medicine - Published
- 2023
- Full Text
- View/download PDF
4. Heart failure and the risk of left atrial thrombus formation in patients with atrial fibrillation or atrial flutter
- Author
-
Maciej T. Wybraniec, Magdalena Mizia‐Szubryt, Małgorzata Cichoń, Karolina Wrona‐Kolasa, Agnieszka Kapłon‐Cieślicka, Monika Gawałko, Monika Budnik, Beata Uziębło‐Życzkowska, Paweł Krzesiński, Katarzyna Starzyk, Iwona Gorczyca‐Głowacka, Ludmiła Daniłowicz‐Szymanowicz, Damian Kaufmann, Maciej Wójcik, Robert Błaszczyk, Jarosław Hiczkiewicz, Katarzyna Łojewska, Katarzyna Kosmalska, Marcin Fijałkowski, Anna Szymańska, Anna Wiktorska, Maciej Haberka, Michał Kucio, Błażej Michalski, Karolina Kupczyńska, Anna Tomaszuk‐Kazberuk, Katarzyna Wilk‐Śledziewska, Renata Wachnicka‐Truty, Marek Koziński, Paweł Burchardt, and Katarzyna Mizia‐Stec
- Subjects
Atrial fibrillation ,Atrial flutter ,Left atrial thrombus ,Heart failure ,Transoesophageal echocardiography ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims The aim of the study was to evaluate the prevalence of left atrial thrombus (LAT) on transoesophageal echocardiography (TOE) in patients with atrial fibrillation or atrial flutter (AF/AFl) with reference to the presence of heart failure (HF) and its subtypes. Methods and results The research is a sub‐study of the multicentre, prospective, observational Left Atrial Thrombus on Transoesophageal Echocardiography (LATTEE) registry, which comprised 3109 consecutive patients with AF/AFl undergoing TOE prior to direct current cardioversion or catheter ablation. TOE parameters, including presence of LAT, were compared between patients with and without HF and across different subtypes of HF, including HF with preserved (HFpEF), mid‐range (HFmrEF), and reduced ejection fraction (HFrEF). HF was diagnosed in 1336 patients (43%). HF patients had higher prevalence of LAT than non‐HF patients (12.8% vs. 4.4%; P
- Published
- 2022
- Full Text
- View/download PDF
5. Jak opiekować się pacjentem z niewydolnością serca i wielochorobowością w POZ? Jakie badania i komu zlecać?
- Author
-
Ochijewicz, Dorota, primary and Kapłon-Cieślicka, Agnieszka, additional
- Published
- 2023
- Full Text
- View/download PDF
6. Metabolic syndrome – a new definition and management guidelines. A joint position paper by the Polish Society of Hypertension, Polish Society for the Treatment of Obesity, Polish Lipid Association, Polish Association for Study of Liver, Polish Society of Family Medicine, Polish Society of Lifestyle Medicine, Division of Prevention and Epidemiology Polish Cardiac Society, 'Club 30' Polish Cardiac Society, and Division of Metabolic and Bariatric Surgery Society of Polish Surgeons
- Author
-
Piotr Dobrowolski, Aleksander Prejbisz, Alina Kuryłowicz, Alicja Baska, Paweł Burchardt, Krzysztof Chlebus, Grzegorz Dzida, Piotr Jankowski, Jerzy Jaroszewicz, Paweł Jaworski, Karol Kamiński, Agnieszka Kapłon-Cieślicka, Marek Klocek, Michał Kukla, Artur Mamcarz, Agnieszka Mastalerz-Migas, Krzysztof Narkiewicz, Lucyna Ostrowska, Daniel Śliż, Wiesław Tarnowski, Jacek Wolf, Mariusz Wyleżoł, Tomasz Zdrojewski, Maciej Banach, Andrzej Januszewicz, and Paweł Bogdański
- Subjects
Medicine - Published
- 2022
- Full Text
- View/download PDF
7. Echocardiographic predictors of thrombus in left atrial appendage—The role of novel transthoracic parameters
- Author
-
Damian Kaufmann, Elżbieta Wabich, Agnieszka Kapłon-Cieślicka, Monika Gawałko, Monika Budnik, Beata Uziębło-Życzkowska, Paweł Krzesiński, Katarzyna Starzyk, Beata Wożakowska-Kapłon, Maciej Wójcik, Robert Błaszczyk, Jarosław Hiczkiewicz, Jan Budzianowski, Katarzyna Mizia-Stec, Maciej T. Wybraniec, Katarzyna Kosmalska, Marcin Fijałkowski, Anna Szymańska, Mirosław Dłużniewski, Maciej Haberka, Michał Kucio, Błażej Michalski, Karolina Kupczyńska, Anna Tomaszuk-Kazberuk, Katarzyna Wilk-Śledziewska, Renata Wachnicka-Truty, Marek Koziński, Paweł Burchardt, and Ludmiła Daniłowicz-Szymanowicz
- Subjects
transthoracic echocardiography ,left atrial appendage thrombus ,NOAC ,echocardiographic indices ,thromboembolic risk ,predictors of left atrial thrombus ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
IntroductionThe left atrium appendage thrombus (LAAT) formation is a complex process. A CHA2DS2-VASc scale is an established tool for determining the thromboembolic risk and initiation of anticoagulation treatment in patients with atrial fibrillation or flutter (AF/AFL). We aimed to identify whether any transthoracic echocardiography (TTE) parameters could have an additional impact on LAAT detection.MethodsThat is a sub-study of multicenter, prospective, observational study LATTEE (NCT03591627), which enrolled 3,109 consecutive patients with AF/AFL referred for transesophageal echocardiography (TEE) before cardioversion or ablation.ResultsLAAT was diagnosed in 8.0% of patients. The univariate logistic regression analysis [based on pre-specified in the receiver operating characteristic (ROC) analysis cut-off values with AUC ≥ 0.7] identified left ventricular ejection fraction (LVEF) ≤ 48% and novel TTE parameters i.e., the ratios of LVEF and left atrial diameter (LAD) ≤ 1.1 (AUC 0.75; OR 5.64; 95% CI 4.03–7.9; p < 0.001), LVEF to left atrial area (LAA) ≤ 1.7 (AUC 0.75; OR 5.64; 95% CI 4.02–7.9; p < 0.001), and LVEF to indexed left atrial volume (LAVI) ≤ 1.1 (AUC 0.75, OR 6.77; 95% CI 4.25–10.8; p < 0.001) as significant predictors of LAAT. In a multivariate logistic regression analysis, LVEF/LAVI and LVEF/LAA maintained statistical significance. Calculating the accuracy of the abovementioned ratios according to the CHA2DS2-VASc scale values revealed their highest predictive power for LAAT in a setting with low thromboembolic risk.ConclusionNovel TTE indices could help identify patients with increased probability of the LAAT, with particular applicability for patients at low thromboembolic risk.
- Published
- 2022
- Full Text
- View/download PDF
8. Risk factors for left atrial thrombus in younger patients (aged < 65 years) with atrial fibrillation or atrial flutter: Data from the multicenter left atrial thrombus on transesophageal echocardiography (LATTEE) registry
- Author
-
Beata Uziȩbło-Życzkowska, Agnieszka Kapłon-Cieślicka, Monika Gawałko, Monika Budnik, Katarzyna Starzyk, Beata Wożakowska-Kapłon, Ludmiła Daniłowicz-Szymanowicz, Damian Kaufmann, Maciej Wójcik, Robert Błaszczyk, Jarosław Hiczkiewicz, Katarzyna Łojewska, Katarzyna Mizia-Stec, Maciej Wybraniec, Katarzyna Kosmalska, Marcin Fijałkowski, Anna Szymańska, Aleksandra Gos, Maciej Haberka, Michał Kucio, Błazej Michalski, Karolina Kupczyńska, Anna Tomaszuk-Kazberuk, Katarzyna Wilk-Śledziewska, Renata Wachnicka-Truty, Marek Koziński, Paweł Burchardt, and Paweł Krzesiński
- Subjects
atrial fibrillation ,thromboembolic risk factors ,young age group ,left atrial thrombus ,transesophageal echocardiography ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
BackgroundOur aim was to assess the characteristics and to identify predictors of left atrial thrombus (LAT) in patients under age 65 with atrial fibrillation (AF) or atrial flutter (AFl).MethodsWe conducted a subanalysis of a multicenter, prospective, observational study [the LATTEE registry]. Consecutive AF/AFl patients referred for cardioversion or ablation were enrolled.ResultsOf the 3,109 patients included in the study, 1,276 were under age 65 (41%). Compared to non-LAT patients, those with LAT (n = 76) had higher CHA2DS2-VASc score (p < 0.001), more frequently had non-paroxysmal AF/AFl (p < 0.001), heart failure (p < 0.001), history of diabetes mellitus (p = 0.001), transient ischemic attack (p = 0.04), coronary artery disease (p = 0.02), and chronic kidney disease (p < 0.001). The LAT patients were also more often smokers (p = 0.004) and were more frequently treated with vitamin K antagonists (VKAs) (p < 0.001). Transthoracic echocardiography revealed a higher left atrial area (p < 0.001), lower left ventricular ejection fraction (LVEF) (p < 0.001), and lower value of LA appendage emptying volume in LAT than in non-LAT patients (p < 0.001). LVEF (OR 2.95; 95% CI: 1.32–6.59, p = 0.008), non-paroxysmal AF/AFl (OR 7.1; 95% CI: 2.05–24.63, p = 0.002) and treatment with VKAs (OR 4.92; 95% CI: 2.48–9.75, p < 0.001) were identified as independent predictors of LAT in younger patients.ConclusionsOur study, which focused on younger patients with AF/AFl, indicated substantial clinical and echocardiographic differences between participants with and without LAT. In the AF/AFl patients younger than age 65, the independent predictors of LAT included non-paroxysmal AF/AFl, lower LVEF, and treatment with VKAs.
- Published
- 2022
- Full Text
- View/download PDF
9. Stand-Alone Left Atrial appendage occlusion for throMboembolism prevention in nonvalvular Atrial fibrillatioN DiseasE Registry (SALAMANDER): protocol for a prospective observational nationwide study
- Author
-
Agnieszka Kapłon-Cieślicka, Maciej Lesiak, Wojciech Wojakowski, Slawomir Dobrzycki, Mariusz Kowalewski, Krzysztof Reczuch, Roberto Lorusso, Michalina Kołodziejczak, Wojciech Wańha, Radoslaw Litwinowicz, Michal Pasierski, Rafal Januszek, Łukasz Kuźma, Marek Grygier, Robert Gil, Tomasz Pawłowski, Krzysztof Bartuś, Stanislaw Bartuś, Marek Andrzej Deja, Grzegorz Smolka, and Piotr Suwalski
- Subjects
Medicine - Abstract
Introduction Atrial fibrillation (AF) is a prevalent disease considerably contributing to the worldwide cardiovascular burden. For patients at high thromboembolic risk (CHA2DS2-VASc ≥3) and not suitable for chronic oral anticoagulation, owing to history of major bleeding or other contraindications, left atrial appendage occlusion (LAAO) is indicated for stroke prevention, as it lowers patient’s ischaemic burden without augmentation in their anticoagulation profile.Methods and analysis Stand-Alone Left Atrial appendage occlusion for throMboembolism prevention in nonvalvular Atrial fibrillatioN DiseasE Registry (SALAMANDER) will be conducted in 10 heart surgery and cardiology centres across Poland to assess the outcomes of LAAO performed by fully thoracoscopic-epicardial, percutaneous-endocardial or hybrid endo-epicardial approach. The registry will include patients with nonvalvular AF at a high risk of thromboembolic and bleeding complications (CHA2DS2-VASc Score ≥2 for males, ≥3 for females, HASBLED score ≥2) referred for LAAO. The first primary outcome is composite procedure-related complications, all-cause death or major bleeding at 12 months. The second primary outcome is a composite of ischaemic stroke or systemic embolism at 12 months. The third primary outcome is the device-specific success assessed by an independent core laboratory at 3–6 weeks. The quality of life (QoL) will be assessed as well based on the QoL EQ-5D-5L questionnaire. Medication and drug adherence will be assessed as well.Ethics and dissemination Before enrolment, a detailed explanation is provided by the investigator and patients are given time to make an informed decision. The patient’s data will be protected according to the requirements of Polish law, General Data Protection Regulation (GDPR) and hospital Standard Operating Procedures. The study will be conducted in accordance with the Declaration of Helsinki. Ethical approval was granted by the local Bioethics Committee of the Upper-Silesian Medical Centre of the Silesian Medical University in Katowice (decision number KNW/0022/KB/284/19). The results will be published in peer-reviewed journals and presented during national and international conferences.Trial registration number NCT05144958.
- Published
- 2022
- Full Text
- View/download PDF
10. Risk of left atrial appendage thrombus in older patients with atrial fibrillation
- Author
-
Monika Gawałko, Monika Budnik, Beata Uziębło-Życzkowska, Iwona Gorczyca, Paweł Krzesiński, Piotr Scisło, Janusz Kochanowski, Anna Michalska, Olga Jelonek, Katarzyna Starzyk, Agnieszka Jurek, Marek Kiliszek, Beata Wożakowska-Kapłon, Grzegorz Gielerak, Krzysztof J. Filipiak, Grzegorz Opolski, and Agnieszka Kapłon-Cieślicka
- Subjects
thromboembolic risk ,age ,stroke prevention ,oral anticoagulation ,Medicine - Abstract
Introduction We aimed to compare the prevalence of left atrial appendage (LAA) thrombus and its predictors between old and young patients with atrial fibrillation (AF). Material and methods The study included 1970 patients aged ≥ 65 (n = 822 (41.7%)) and < 65 (n = 1148 (58.3%)) referred for AF cardioversion or ablation preceded by transoesophageal echocardiography (TEE). Results Oral anticoagulation (OAC) was prescribed in 799 (97.2%) patients aged ≥ 65 years and in 1054 (91.8%) of those aged < 65 years (p < 0.001). In patients treated with OAC, those aged ≥ 65 years less often received vitamin K antagonist (VKA) (267 (33.4%) vs. 416 (39.5%)) and more often non-VKA-OAC (NOAC) (532 (66.6%) vs. 638 (60.5%), p = 0.008, p = 0.008) compared to patients < 65 years. On TEE, LAA thrombus was more often observed in patients aged ≥ 65 years than those aged < 65 years (63 (7.7%) vs. 46 (4.0%), p < 0.001), with an absolute but not statistically significant difference between patients aged 65–74 and ≥ 75 years (47 (7.3%) vs. 16 (8.8%), p = 0.528). In patients aged ≥ 65 years, there was no difference in the prevalence of LAA thrombus between patients treated with VKA and NOAC, in contrast to patients aged < 65 years, in whom such a difference was observed (27 (6.5%) vs. 16 (2.5%), p = 0.002). In multivariate logistic regression, predictors of LAA thrombus in both age groups were older age, non-paroxysmal AF, and heart failure, whereas only in patients aged < 65 years – VKA use, and in those aged ≥ 65 years – lower glomerular filtration rate and platelet count. Conclusions Despite OAC use, older patients with AF remain at high risk of LAA thrombus formation. Older age, non-paroxysmal AF, and heart failure are predictors of LAA thrombus, irrespective of age.
- Published
- 2021
- Full Text
- View/download PDF
11. Clinical and echocardiographic characterization of patients hospitalized for severe tricuspid valve regurgitation: a single tertiary-care center experience with 2-year follow-up.
- Author
-
Piasecki, Adam, Tomaniak, Mariusz, Gumiężna, Karolina, Kurzyna, Paweł, Bednarek, Adrian, Skulimowska, Julia, Pędzich, Ewa, Kapłon-Cieślicka, Agnieszka, Rdzanek, Adam, and Scislo, Piotr
- Published
- 2024
- Full Text
- View/download PDF
12. Can transesophageal echocardiography be safely omitted in patients scheduled for elective ablation of atrial arrhythmias? Data based on the LATTEE registry.
- Author
-
Kaufmann, Damian, Królak, Tomasz, Dąbrowska-Kugacka, Alicja, Kapłon-Cieślicka, Agnieszka, Gawałko, Monika, Budnik, Monika, Uziębło-Życzkowska, Beata, Krzesiński, Paweł, Starzyk, Katarzyna, Wożakowska-Kapłon, Beata, Wójcik, Maciej, Błaszczyk, Robert, Hiczkiewicz, Jarosław, Budzianowski, Jan, Mizia-Stec, Katarzyna, Wybraniec, Maciej T., Kosmalska, Katarzyna, Fijałkowski, Marcin, Szymańska, Anna, and Dłużniewski, Mirosław
- Published
- 2024
- Full Text
- View/download PDF
13. Do we need a definition of acute heart failure with preserved ejection fraction?
- Author
-
Agnieszka Kapłon-Cieślicka and Lars H. Lund
- Subjects
Heart failure with preserved ejection fraction ,heart failure decompensation ,diastolic dysfunction ,diagnosis ,Medicine - Abstract
AbstractHeart failure with preserved ejection fraction (HFpEF) might soon become the most prevalent type of acute heart failure. Still, despite more than 30 years of research on HFpEF, not only do we lack specific treatment, but also a generally accepted definition of HFpEF. Since 2016, several definitions and algorithms have been proposed for diagnosing both diastolic dysfunction and overt HFpEF. However, all of them focus exclusively on chronic (and not acute) HFpEF. Recent studies showed that acute HFpEF may be overdiagnosed in patients presenting with acute dyspnoea. The aim of our article was to address two questions: (1) why there is a need for specific diagnostic criteria for acute HFpEF, and (2) what such definition of acute HFpEF should encompass.KEY MESSAGES:Several scores and algorithms have been proposed for diagnosing chronic heart failure with preserved ejection fraction (HFpEF), however, so far, there is no definition of acute HFpEF.Acute HFpEF seems to be overdiagnosed in patients presenting with acute dyspnoea.Definition of acute HFpEF should comprise both (1) features of chronic HFpEF and (2) markers of increased left ventricular filling pressures and/or of pulmonary congestion.
- Published
- 2021
- Full Text
- View/download PDF
14. Do Patients With Acute Heart Failure and Preserved Ejection Fraction Have Heart Failure at Follow-Up: Implications of the Framingham Criteria
- Author
-
HAGE, CAMILLA, LÖFSTRÖM, ULRIKA, DONAL, ERWAN, OGER, EMMANUEL, KAPŁON-CIEŚLICKA, AGNIESZKA, DAUBERT, JEAN-CLAUDE, LINDE, CECILIA, and LUND, LARS H.
- Published
- 2020
- Full Text
- View/download PDF
15. Egzamin z kardiologii. Tom 1
- Author
-
Balsam, Paweł, primary, Bielecka-Dąbrowa, Agata, additional, Błach, Anna, additional, Brociek, Emil, additional, Budaj-Fidecka, Anna, additional, Byczkowska, Katarzyna, additional, Chabior, Aleksandra, additional, Cichocka-Radwan, Anna, additional, Czepczor, Kinga, additional, Dobrowolski, Piotr, additional, Domienik-Karłowicz, Justyna, additional, Drożdż, Jarosław, additional, Filipiak-Strzecka, Dominika, additional, Gabryel, Łukasz, additional, Galas, Agata, additional, Gąsior, Zbigniew, additional, Gierlotka, Marek, additional, Góral, Piotr, additional, Holcman, Katarzyna, additional, Imiela, Anna, additional, Imiela, Tomasz, additional, Januszewicz, Andrzej, additional, Januszewicz, Magdalena, additional, Jedrzejczyk-Patej, Ewa, additional, Kapłon-Cieślicka, Agnieszka, additional, Kasperowicz, Krzysztof, additional, Kępski, Jarosław, additional, Kopeć, Grzegorz, additional, Kosiński, Przemysław, additional, Kozłowska, Bogna, additional, Krzesiński, Paweł, additional, Krzowski, Bartosz, additional, Kupczyńska, Karolina, additional, Kurzyna, Marcin, additional, Kuśmierczyk, Mariusz, additional, Lelonek, Małgorzata, additional, Lenarczyk, Radosław, additional, Leszek, Przemysław, additional, Lipiec, Piotr, additional, Mazurek, Michał, additional, Mielczarek, Szymon, additional, Mizia-Stec, Katarzyna, additional, Morawiec, Robert, additional, Nowak, Marcin M., additional, Ochijewicz, Dorota, additional, Opolski, Grzegorz, additional, Ozierański, Krzysztof, additional, Pasierski, Michał, additional, Pawlak, Agnieszka, additional, Piątkowski, Radosław, additional, Podolski, Maciej, additional, Prejbisz, Aleksander, additional, Pyziak-Stepień, Marta, additional, Rajska, Ewa, additional, Rubiś, Paweł, additional, Rymuza, Bartosz, additional, Sacha, Jerzy, additional, Skrobucha, Alicja, additional, Słomka, Sebastian, additional, Sobieszczańska-Małek, Małgorzata, additional, Sokolska, Justyna M., additional, Stępniewski, Jakub, additional, Suwalski, Piotr, additional, Szczerba, Ewa, additional, Szmit, Sebastian, additional, Szymański, Piotr, additional, Tomaszek, Aleksandra, additional, Torbicki, Adam, additional, Tymińska, Agata, additional, Wieteska-Mirek, Maria, additional, Witowicz, Anna, additional, Wojakowski, Wojciech, additional, Wrona, Katarzyna, additional, Załęska-Kocięcka, Marta, additional, Zawadka, Mateusz, additional, and Żurawska, Małgorzata, additional
- Published
- 2024
- Full Text
- View/download PDF
16. Egzamin z kardiologii. Tom 3
- Author
-
Balsam, Paweł, primary, Blamek, Sławomir, additional, Błach, Anna, additional, Braksator, Wojciech, additional, Budaj-Fidecka, Anna, additional, Budnik, Monika, additional, Burban, Anna, additional, Ciepłucha, Aleksandra, additional, Ciurzyński, Michał, additional, Czupryniak, Leszek, additional, Darocha, Szymon, additional, Dąbrowski, Rafał, additional, Dorniak, Karolina, additional, Dyrbuś, Maciej, additional, Dziewięcka, Ewa, additional, Elwertowski, Michał, additional, Ferens, Antoni, additional, Fojt, Anna, additional, Gackowski, Andrzej, additional, Gajewska, Magdalena, additional, Gajos, Grzegorz, additional, Gałązka, Zbigniew, additional, Gawałko, Monika, additional, Gąsecka, Aleksandra, additional, Główczynska, Renata, additional, Grabowski, Marcin, additional, Grodecki, Kajetan, additional, Haberka, Maciej, additional, Huczek, Zenon, additional, Januszkiewicz, Łukasz, additional, Jędrzejczyk-Patej, Ewa, additional, Jonik, Szymon, additional, Kapłon-Cieślicka, Agnieszka, additional, Kaszczewski, Piotr, additional, Kazimierczyk, Ewelina, additional, Kazimierczyk, Remigiusz, additional, Kępka, Cezary, additional, Kobylecka, Małgorzata, additional, Kochman, Janusz, additional, Kołodzińska, Agnieszka, additional, Kołtowski, Łukasz, additional, Konwerski, Michał, additional, Kosek-Nikołajczuk, Małgorzata, additional, Kowalik, Robert, additional, Kowara, Michał, additional, Kozyra-Pydyś, Eliza, additional, Koźluk, Edward, additional, Król, Wojciech, additional, Krzowski, Bartosz, additional, Kupczyńska, Karolina, additional, Kurnicka, Katarzyna, additional, Kuśmierczyk, Mariusz, additional, Kwieciński, Jacek, additional, Lenarczyk, Radosław, additional, Lichodziejewska, Barbara, additional, Lodziński, Piotr, additional, Maciejewski, Cezary, additional, Małecki, Robert, additional, Małyszko, Jolanta, additional, Mamcarz, Artur, additional, Marchel, Michał, additional, Mazurek, Maciej, additional, Mazurek, Michał, additional, Męcka, Klaudia, additional, Miśkowiec, Dawid, additional, Mizia-Stec, Katarzyna, additional, Ochotny, Romuald, additional, Opolski, Maksymilian P., additional, Oręziak, Artur, additional, Orszulak, Michał, additional, Ostrowska, Ewa, additional, Ozierański, Krzysztof, additional, Pachciński, Olaf, additional, Pasierski, Michał, additional, Peller, Michał, additional, Petryka-Mazurkiewicz, Joanna, additional, Piątkowska, Agnieszka, additional, Piotrowicz, Ewa, additional, Piotrowicz, Ryszard, additional, Pruszczyk, Piotr, additional, Rajewska-Tabor, Justyna, additional, Rogozik, Joanna, additional, Rogula, Sylwester, additional, Rokicki, Jakub, additional, Ryś-Czaporowska, Anna, additional, Stępień-Adamczewska, Violetta, additional, Stępińska, Janina, additional, Strzelczyk, Jakub, additional, Styczyński, Grzegorz, additional, Suwalski, Piotr, additional, Szczałuba, Krzysztof, additional, Szczerba, Ewa, additional, Śpiewak, Mateusz, additional, Świerżyńska, Ewa, additional, Tajstra, Mateusz, additional, Tomaniak, Mariusz, additional, Tycińska, Agnieszka, additional, Tymińska, Agata, additional, Wełnicki, Marcin, additional, Winciunas, Piotr Artur, additional, and Zaleska, Martyna, additional
- Published
- 2024
- Full Text
- View/download PDF
17. Oral anticoagulation therapy in patients with atrial fibrillation at high risk of bleeding: Clinical characteristics and treatment strategies based on data from the Polish Multi-center Register of Atrial Fibrillation (POL-AF)
- Author
-
Maciorowska, Małgorzata, primary, Uziębło-Życzkowska, Beata, additional, Gorczyca-Głowacka, Iwona, additional, Wożakowska-Kapłon, Beata, additional, Jelonek, Olga, additional, Wójcik, Maciej, additional, Błaszczyk, Robert, additional, Kapłon-Cieślicka, Agnieszka, additional, Gawałko, Monika, additional, Tokarek, Tomasz, additional, Rajtar-Salwa, Renata, additional, Bil, Jacek, additional, Wojewódzki, Michał, additional, Szpotowicz, Anna, additional, Krzciuk, Małgorzata, additional, Bednarski, Janusz, additional, Bakuła-Ostalska, Elwira, additional, Tomaszuk-Kazberuk, Anna, additional, Szyszkowska, Anna, additional, Wełnicki, Marcin, additional, Mamcarz, Artur, additional, and Krzesiński, Paweł, additional
- Published
- 2023
- Full Text
- View/download PDF
18. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association
- Author
-
Banach, Maciej, primary, Surma, Stanisław, additional, Kapłon-Cieślicka, Agnieszka, additional, Mitkowski, Przemysław, additional, Dzida, Grzegorz, additional, Tomasik, Tomasz, additional, and Mastalerz-Migas, Agnieszka, additional
- Published
- 2023
- Full Text
- View/download PDF
19. Is heart failure misdiagnosed in hospitalized patients with preserved ejection fraction? From the European Society of Cardiology ‐ Heart Failure Association EURObservational Research Programme Heart Failure Long‐Term Registry
- Author
-
Agnieszka Kapłon‐Cieślicka, Cécile Laroche, Maria G. Crespo‐Leiro, Andrew J.S. Coats, Stefan D. Anker, Gerasimos Filippatos, Aldo P. Maggioni, Camilla Hage, Antonio Lara‐Padrón, Alessandro Fucili, Jarosław Drożdż, Petar Seferovic, Giuseppe M.C. Rosano, Alexandre Mebazaa, Theresa McDonagh, Mitja Lainscak, Frank Ruschitzka, Lars H. Lund, and Heart Failure Association (HFA) of the European Society of Cardiology (ESC) and the ESC Heart Failure Long‐Term Registry Investigators
- Subjects
Comorbidity ,Death ,Diastolic dysfunction ,Heart failure with preserved ejection fraction ,Hospitalization ,Overdiagnosis ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Abstract Aims In hospitalized patients with a clinical diagnosis of acute heart failure (HF) with preserved ejection fraction (HFpEF), the aims of this study were (i) to assess the proportion meeting the 2016 European Society of Cardiology (ESC) HFpEF criteria and (ii) to compare patients with restrictive/pseudonormal mitral inflow pattern (MIP) vs. patients with MIP other than restrictive/pseudonormal. Methods and results We included hospitalized participants of the ESC‐Heart Failure Association (HFA) EURObservational Research Programme (EORP) HF Long‐Term Registry who had echocardiogram with ejection fraction (EF) ≥ 50% during index hospitalization. As no data on e', E/e' and left ventricular (LV) mass index were gathered in the registry, the 2016 ESC HFpEF definition was modified as follows: elevated B‐type natriuretic peptide (BNP) (≥100 pg/mL for acute HF) and/or N‐terminal pro‐BNP (≥300 pg/mL) and at least one of the echocardiographic criteria: (i) presence of LV hypertrophy (yes/no), (ii) left atrial volume index (LAVI) of >34 mL/m2), or (iii) restrictive/pseudonormal MIP. Next, all patients were divided into four groups: (i) patients with restrictive/pseudonormal MIP on echocardiography [i.e. with presumably elevated left atrial (LA) pressure], (ii) patients with MIP other than restrictive/pseudonormal (i.e. with presumably normal LA pressure), (iii) atrial fibrillation (AF) group, and (iv) ‘grey area’ (no consistent description of MIP despite no report of AF). Of 6365 hospitalized patients, 1848 (29%) had EF ≥ 50%. Natriuretic peptides were assessed in 28%, LV hypertrophy in 92%, LAVI in 13%, and MIP in 67%. The 2016 ESC HFpEF criteria could be assessed in 27% of the 1848 patients and, if assessed, were met in 52%. Of the 1848 patients, 19% had restrictive/pseudonormal MIP, 43% had MIP other than restrictive/pseudonormal, 18% had AF and 20% were grey area. There were no differences in long‐term all‐cause or cardiovascular mortality, or all‐cause hospitalizations or HF rehospitalizations between the four groups. Despite fewer non‐cardiac comorbidities reported at baseline, patients with MIP other than restrictive/pseudonormal (i.e. with presumably normal LA pressure) had more non‐cardiovascular (14.0 vs. 6.7 per 100 patient‐years, P
- Published
- 2020
- Full Text
- View/download PDF
20. Randomized controlled trial protocol to investigate the antiplatelet therapy effect on extracellular vesicles (AFFECT EV) in acute myocardial infarction
- Author
-
Aleksandra Gasecka, Rienk Nieuwland, Monika Budnik, Françoise Dignat-George, Ceren Eyileten, Paul Harrison, Zenon Huczek, Agnieszka Kapłon-Cieślicka, Romaric Lacroix, Grzegorz Opolski, Kinga Pluta, Edwin van der Pol, Marek Postuła, Aurélie Leroyer, Pia Siljander, Auguste Sturk, and Krzysztof J. Filipiak
- Subjects
adp receptors ,extracellular vesicles ,p2y12 antagonists ,platelets ,ticagrelor ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Activated platelets contribute to thrombosis and inflammation by the release of extracellular vesicles (EVs) exposing P-selectin, phosphatidylserine (PS) and fibrinogen. P2Y12 receptor antagonists are routinely administered to inhibit platelet activation in patients after acute myocardial infarction (AMI), being a combined antithrombotic and anti-inflammatory therapy. The more potent P2Y12 antagonist ticagrelor improves cardiovascular outcome in patients after AMI compared to the less potent clopidogrel, suggesting that greater inhibition of platelet aggregation is associated with better prognosis. The effect of ticagrelor and clopidogrel on the release of EVs from platelets and other P2Y12-exposing cells is unknown. This study compares the effects of ticagrelor and clopidogrel on (1) the concentrations of EVs from activated platelets (primary end point), (2) the concentrations of EVs exposing fibrinogen, exposing PS, from leukocytes and from endothelial cells (secondary end points) and (3) the procoagulant activity of plasma EVs (tertiary end points) in 60 consecutive AMI patients. After the percutaneous coronary intervention, patients will be randomized to antiplatelet therapy with ticagrelor (study group) or clopidogrel (control group). Blood will be collected from patients at randomization, 48 hours after randomization and 6 months following the index hospitalization. In addition, 30 age- and gender-matched healthy volunteers will be enrolled in the study to investigate the physiological concentrations and procoagulant activity of EVs using recently standardized protocols and EV-dedicated flow cytometry. Concentrations of EVs will be determined by flow cytometry. Procoagulant activity of EVs will be determined by fibrin generation test. The compliance and response to antiplatelet therapy will be assessed by impedance aggregometry. We expect that plasma from patients treated with ticagrelor (1) contains lower concentrations of EVs from activated platelets, exposing fibrinogen, exposing PS, from leukocytes and from endothelial cells and (2) has lower procoagulant activity, when compared to patients treated with clopidogrel. Antiplatelet therapy effect on EVs may identify a new mechanism of action of ticagrelor, as well as create a basis for future studies to investigate whether lower EV concentrations are associated with improved clinical outcomes in patients treated with P2Y12 antagonists.
- Published
- 2020
- Full Text
- View/download PDF
21. Increased Body Mass Index and Risk of Left Atrial Thrombus in Nonvalvular Atrial Fibrillation Patients—Data from the Left Atrial Thrombus on Transesophageal Echocardiography (LATTEE) Registry
- Author
-
Beata Uziębło-Życzkowska, Agnieszka Kapłon-Cieślicka, Marek Kiliszek, Monika Gawałko, Monika Budnik, Katarzyna Starzyk, Beata Wożakowska-Kapłon, Ludmiła Daniłowicz-Szymanowicz, Damian Kaufmann, Maciej Wójcik, Robert Błaszczyk, Jarosław Hiczkiewicz, Katarzyna Łojewska, Katarzyna Mizia-Stec, Maciej T. Wybraniec, Katarzyna Kosmalska, Marcin Fijałkowski, Anna Szymańska, Aleksandra Gos, Maciej Haberka, Michał Kucio, Błażej Michalski, Karolina Kupczyńska, Anna Tomaszuk-Kazberuk, Katarzyna Wilk-Śledziewska, Renata Wachnicka-Truty, Marek Koziński, Paweł Burchardt, and Paweł Krzesiński
- Subjects
atrial fibrillation ,atrial flutter ,body mass index ,left atrial thrombus ,Nutrition. Foods and food supply ,TX341-641 - Abstract
An increased body mass index (BMI) is associated with a higher incidence of atrial fibrillation (AF) and a higher risk of thromboembolic complications in AF patients. The aim of this study was to investigate the effect of BMI on the risk of left atrial thrombi (LATs) in patients with nonvalvular AF/atrial flutter (AFl) (NV AF/AFl). Patients diagnosed with NVAF/AFl (between November 2018 and May 2020) were selected from the multicenter, prospective, observational Left Atrial Thrombus on Transesophageal Echocardiography (LATTEE) registry that included AF/AFl patients referred for cardioversion or ablation followed by transesophageal echocardiography. A total of 2816 AF/AFl patients (63.6% males; mean age 65.8 years; mean BMI 29.8 kg/m2) were included in the study. Two hundred and twenty-two of them (7.9%) had LATs. Compared with normal-weight patients, those with BMIs ≥ 25 kg/m2 more frequently presented clinical factors potentially provoking LATs, such as non-paroxysmal AF/AFl (p = 0.04), hypertension (p < 0.001), and diabetes (p < 0.001); had higher CHA2DS2 scores (p < 0.001); and had larger LA dimensions (LA diameter and LA area) (p < 0.001 for both parameters). On the other hand, they showed some features negatively related to thromboembolic risk; for example, they were younger (p < 0.001) and were more often male (p = 0.002). In addition, patients with abnormal BMIs were more likely to be smokers (p = 0.006) and to be treated with oral anticoagulants (p = 0.005). Despite these differences in the prevalence of thromboembolic risk factors, the incidence of LATs was not increased in patients with abnormal body weight (overweight and obese compared to normal-weight patients) in this large real-life cohort of AF/AFl patients. This is probably due to the balanced composition regarding the prevalence of positive and negative thromboembolic risk factors.
- Published
- 2022
- Full Text
- View/download PDF
22. Serum Brain-Derived Neurotrophic Factor is Related to Platelet Reactivity and Metformin Treatment in Adult Patients With Type 2 Diabetes Mellitus
- Author
-
Eyileten, Ceren, Mirowska-Guzel, Dagmara, Milanowski, Lukasz, Zaremba, Malgorzata, Rosiak, Marek, Cudna, Agnieszka, Kaplon-Cieslicka, Agnieszka, Opolski, Grzegorz, Filipiak, Krzysztof J., Malek, Lukasz, and Postula, Marek
- Published
- 2019
- Full Text
- View/download PDF
23. Fifteen-Year Differences in Indications for Cardiac Resynchronization Therapy in International Guidelines—Insights from the Heart Failure Registries of the European Society of Cardiology
- Author
-
Agata Tymińska, Krzysztof Ozierański, Emil Brociek, Agnieszka Kapłon-Cieślicka, Paweł Balsam, Michał Marchel, Maria G. Crespo-Leiro, Aldo P. Maggioni, Jarosław Drożdż, Grzegorz Opolski, and Marcin Grabowski
- Subjects
cardiac resynchronization therapy ,heart failure ,cardiomyopathy ,left bundle branch block ,Medicine - Abstract
Cardiac resynchronization therapy (CRT) applied to selected patients with heart failure (HF) improves their prognosis. In recent years, eligibility criteria for CRT have regularly changed. This study aimed to investigate the changes in eligibility of real-life HF patients for CRT over the past fifteen years. We reviewed European and North American guidelines from this period and applied them to HF patients from the ESC-HF Pilot and ESC-Long-Term Registries. Taking into consideration the criteria assessed in this study (including all classes of recommendations i.e., class I, IIa and IIb, as well as patients with AF and SR), the 2013 (ESC) guidelines would have qualified the most patients for CRT (266, 18.3%), while the 2015 (ESC) guidelines would have qualified the least (115, 7.9%; p-value for differences between all analyzed papers
- Published
- 2022
- Full Text
- View/download PDF
24. Left Atrial Thrombus in Atrial Fibrillation/Flutter Patients in Relation to Anticoagulation Strategy: LATTEE Registry
- Author
-
Agnieszka Kapłon-Cieślicka, Monika Gawałko, Monika Budnik, Beata Uziębło-Życzkowska, Paweł Krzesiński, Katarzyna Starzyk, Iwona Gorczyca-Głowacka, Ludmiła Daniłowicz-Szymanowicz, Damian Kaufmann, Maciej Wójcik, Robert Błaszczyk, Jarosław Hiczkiewicz, Katarzyna Łojewska, Katarzyna Mizia-Stec, Maciej T Wybraniec, Katarzyna Kosmalska, Marcin Fijałkowski, Anna Szymańska, Mirosław Dłużniewski, Maciej Haberka, Michał Kucio, Błażej Michalski, Karolina Kupczyńska, Anna Tomaszuk-Kazberuk, Katarzyna Wilk-Śledziewska, Renata Wachnicka-Truty, Marek Koziński, Paweł Burchardt, Piotr Scisło, Radosław Piątkowski, Janusz Kochanowski, Grzegorz Opolski, and Marcin Grabowski
- Subjects
thromboembolic risk ,apixaban ,dabigatran ,rivaroxaban ,transesophageal echocardiography ,Medicine - Abstract
Background: Atrial fibrillation (AF) and flutter (AFl) increase the risk of thromboembolism. The aim of the study was to assess the prevalence of left atrial thrombus (LAT) in AF/AFl in relation to oral anticoagulation (OAC). Methods: LATTEE (NCT03591627) was a multicenter, prospective, observational study enrolling consecutive patients with AF/AFl referred for transesophageal echocardiography before cardioversion or ablation. Results: Of 3109 patients enrolled, 88% were on chronic, 1.5% on transient OAC and 10% without OAC. Of patients on chronic OAC, 39% received rivaroxaban, 30% dabigatran, 14% apixaban and 18% vitamin K antagonists (VKA). Patients on apixaban were oldest, had the worst renal function and were highest in both bleeding and thromboembolic risk, and more often received reduced doses. Prevalence of LAT was 8.0% (7.3% on chronic OAC vs. 15% without OAC; p < 0.01). In patients on VKA, prevalence of LAT was doubled compared to patients on non-VKA-OACs (NOACs) (13% vs. 6.0%; p < 0.01), even after propensity score weighting (13% vs. 7.5%; p < 0.01). Prevalence of LAT in patients on apixaban was higher (9.8%) than in those on rivaroxaban (5.7%) and dabigatran (4.7%; p < 0.01 for both comparisons), however, not after propensity score weighting. Conclusions: The prevalence of LAT in AF is non-negligible even on chronic OAC. The risk of LAT seems higher on VKA compared to NOAC, and similar between different NOACs.
- Published
- 2022
- Full Text
- View/download PDF
25. Performance of Prognostic Risk Scores in Chronic Heart Failure Patients Enrolled in the European Society of Cardiology Heart Failure Long-Term Registry
- Author
-
Crespo-Leiro, M., Anker, S., Mebazaa, A., Coats, A., Filippatos, G., Ferrari, R., Maggioni, A.P., Piepoli, M.F., Amir, O., Chioncel, O., Dahlström, U., Delgado Jimenez, J.F., Drozdz, J., Erglis, A., Fazlibegovic, E., Fonseca, C., Fruhwald, F., Gatzov, P., Goncalvesova, E., Hassanein, M., Hradec, J., Kavoliuniene, A., Lainscak, M., Logeart, D., Merkely, B., Metra, M., Otljanska, M., Seferovic, P.M., Srbinovska Kostovska, E., Temizhan, A., Tousoulis, D., Ferreira, T., Andarala, M., Fiorucci, E., Folkesson Lefrancq, E., Glémot, M., Gracia, G., Konte, M., Laroche, C., McNeill, P.A., Missiamenou, V., Taylor, C., Auer, J., Ablasser, K., Dolze, T., Brandner, K., Gstrein, S., Poelzl, G., Moertl, D., Reiter, S., Podczeck-Schweighofer, A., Muslibegovic, A., Vasilj, M., Cesko, M., Zelenika, D., Palic, B., Pravdic, D., Cuk, D., Vitlianova, K., Katova, T., Velikov, T., Kurteva, T., Kamenova, D., Antova, M., Sirakova, V., Krejci, J., Mikolaskova, M., Spinar, J., Krupicka, J., Malek, F., Hegarova, M., Lazarova, M., Monhart, Z., Sobhy, M., El Messiry, F., El Shazly, A.H., Elrakshy, Y., Youssef, A., Moneim, A.A., Noamany, M., Reda, A., Abdel Dayem, T.K., Farag, N., Ibrahim Halawa, S., Abdel Hamid, M., Said, K., Saleh, A., Ebeid, H., Hanna, R., Aziz, R., Louis, O., Enen, M.A., Ibrahim, B.S., Nasr, G., Elbahry, A., Sobhy, H., Ashmawy, M., Gouda, M., Aboleineen, W., Bernard, Y., Luporsi, P., Meneveau, N., Pillot, M., Morel, M., Seronde, M.-F., Schiele, F., Briand, F., Delahaye, F., Damy, T., Eicher, J.-C., de Groote, P., Fertin, M., Lamblin, N., Isnard, R., Lefol, C., Thevenin, S., Hagege, A., Jondeau, G., Le Marcis, V., Ly, J.-F., Coisne, D., Lequeux, B., Le Moal, V., Mascle, S., Lotton, P., Behar, N., Donal, E., Thebault, C., Ridard, C., Reynaud, A., Basquin, A., Bauer, F., Codjia, R., Galinier, M., Tourikis, P., Stavroula, M., Stefanadis, C., Chrysohoou, C., Kotrogiannis, I., Matzaraki, V., Dimitroula, T., Karavidas, A., Tsitsinakis, G., Kapelios, C., Nanas, J., Kampouri, H., Nana, E., Kaldara, E., Eugenidou, A., Vardas, P., Saloustros, I., Patrianakos, A., Tsaknakis, T., Evangelou, S., Nikoloulis, N., Tziourganou, H., Tsaroucha, A., Papadopoulou, A., Douras, A., Polgar, L., Kosztin, A., Nyolczas, N., Csaba Nagy, A., Halmosi, R., Elber, J., Alony, I., Shotan, A., Vazan Fuhrmann, A., Romano, S., Marcon, S., Penco, M., Di Mauro, M., Lemme, E., Carubelli, V., Rovetta, R., Bulgari, M., Quinzani, F., Lombardi, C., Bosi, S., Schiavina, G., Squeri, A., Barbieri, A., Di Tano, G., Pirelli, S., Fucili, A., Passero, T., Musio, S., Di Biase, M., Correale, M., Salvemini, G., Brognoli, S., Zanelli, E., Giordano, A., Agostoni, P., Italiano, G., Salvioni, E., Copelli, S., Modena, M.G., Reggianini, L., Valenti, C., Olaru, A., Bandino, S., Deidda, M., Mercuro, G., Cadeddu Dessalvi, C., Marino, P.N., Di Ruocco, M.V., Sartori, C., Piccinino, C., Parrinello, G., Licata, G., Torres, D., Giambanco, S., Busalacchi, S., Arrotti, S., Novo, S., Inciardi, R.M., Pieri, P., Chirco, P.R., Ausilia Galifi, M., Teresi, G., Buccheri, D., Minacapelli, A., Veniani, M., Frisinghelli, A., Priori, S.G., Cattaneo, S., Opasich, C., Gualco, A., Pagliaro, M., Mancone, M., Fedele, F., Cinque, A., Vellini, M., Scarfo, I., Romeo, F., Ferraiuolo, F., Sergi, D., Anselmi, M., Melandri, F., Leci, E., Iori, E., Bovolo, V., Pidello, S., Frea, S., Bergerone, S., Botta, M., Canavosio, F.G., Gaita, F., Merlo, M., Cinquetti, M., Sinagra, G., Ramani, F., Fabris, E., Stolfo, D., Artico, J., Miani, D., Fresco, C., Daneluzzi, C., Proclemer, A., Cicoira, M., Zanolla, L., Marchese, G., Torelli, F., Vassanelli, C., Voronina, N., Tamakauskas, V., Smalinskas, V., Karaliute, R., Petraskiene, I., Kazakauskaite, E., Rumbinaite, E., Vysniauskas, V., Brazyte-Ramanauskiene, R., Petraskiene, D., Stankala, S., Switala, P., Juszczyk, Z., Sinkiewicz, W., Gilewski, W., Pietrzak, J., Orzel, T., Kasztelowicz, P., Kardaszewicz, P., Lazorko-Piega, M., Gabryel, J., Mosakowska, K., Bellwon, J., Rynkiewicz, A., Raczak, G., Lewicka, E., Dabrowska-Kugacka, A., Bartkowiak, R., Sosnowska-Pasiarska, B., Wozakowska-Kaplon, B., Krzeminski, A., Zabojszcz, M., Mirek-Bryniarska, E., Grzegorzko, A., Bury, K., Nessler, J., Zalewski, J., Furman, A., Broncel, M., Poliwczak, A., Bala, A., Zycinski, P., Rudzinska, M., Jankowski, L., Kasprzak, J.D., Michalak, L., Wojtczak Soska, K., Huziuk, I., Retwinski, A., Flis, P., Weglarz, J., Bodys, A., Grajek, S., Kaluzna-Oleksy, M., Straburzynska-Migaj, E., Dankowski, R., Szymanowska, K., Grabia, J., Szyszka, A., Nowicka, A., Samcik, M., Wolniewicz, L., Baczynska, K., Komorowska, K., Poprawa, I., Komorowska, E., Sajnaga, D., Zolbach, A., Dudzik-Plocica, A., Abdulkarim, A.-F., Lauko-Rachocka, A., Kaminski, L., Kostka, A., Cichy, A., Ruszkowski, P., Splawski, M., Fitas, G., Szymczyk, A., Serwicka, A., Fiega, A., Zysko, D., Krysiak, W., Szabowski, S., Skorek, E., Pruszczyk, P., Bienias, P., Ciurzynski, M., Welnicki, M., Mamcarz, A., Folga, A., Zielinski, T., Rywik, T., Leszek, P., Sobieszczanska-Malek, M., Piotrowska, M., Kozar-Kaminska, K., Komuda, K., Wisniewska, J., Tarnowska, A., Balsam, P., Marchel, M., Opolski, G., Kaplon-Cieslicka, A., Gil, R.J., Mozenska, O., Byczkowska, K., Gil, K., Pawlak, A., Michalek, A., Krzesinski, P., Piotrowicz, K., Uzieblo-Zyczkowska, B., Stanczyk, A., Skrobowski, A., Ponikowski, P., Jankowska, E., Rozentryt, P., Polonski, L., Gadula-Gacek, E., Nowalany-Kozielska, E., Kuczaj, A., Kalarus, Z., Szulik, M., Przybylska, K., Klys, J., Prokop-Lewicka, G., Kleinrok, A., Tavares Aguiar, C., Ventosa, A., Pereira, S., Faria, R., Chin, J., De Jesus, I., Santos, R., Silva, P., Moreno, N., Queirós, C., Lourenço, C., Pereira, A., Castro, A., Andrade, A., Oliveira Guimaraes, T., Martins, S., Placido, R., Lima, G., Brito, D., Francisco, A.R., Cardiga, R., Proenca, M., Araujo, I., Marques, F., Moura, B., Leite, S., Campelo, M., Silva-Cardoso, J., Rodrigues, J., Rangel, I., Martins, E., Sofia Correia, A., Peres, M., Marta, L., Ferreira da Silva, G., Severino, D., Durao, D., Leao, S., Magalhaes, P., Moreira, I., Filipa Cordeiro, A., Ferreira, C., Araujo, C., Ferreira, A., Baptista, A., Radoi, M., Bicescu, G., Vinereanu, D., Sinescu, C.-J., Macarie, C., Popescu, R., Daha, I., Dan, G.-A., Stanescu, C., Dan, A., Craiu, E., Nechita, E., Aursulesei, V., Christodorescu, R., Otasevic, P., Simeunovic, D., Ristic, A.D., Celic, V., Pavlovic-Kleut, M., Suzic Lazic, J., Stojcevski, B., Pencic, B., Stevanovic, A., Andric, A., Iric-Cupic, V., Jovic, M., Davidovic, G., Milanov, S., Mitic, V., Atanaskovic, V., Antic, S., Pavlovic, M., Stanojevic, D., Stoickov, V., Ilic, S., Deljanin Ilic, M., Petrovic, D., Stojsic, S., Kecojevic, S., Dodic, S., Cemerlic Adic, N., Cankovic, M., Stojiljkovic, J., Mihajlovic, B., Radin, A., Radovanovic, S., Krotin, M., Klabnik, A., Pernicky, M., Murin, J., Kovar, F., Kmec, J., Semjanova, H., Strasek, M., Savnik Iskra, M., Ravnikar, T., Cernic Suligoj, N., Komel, J., Fras, Z., Jug, B., Glavic, T., Losic, R., Bombek, M., Krajnc, I., Krunic, B., Horvat, S., Kovac, D., Rajtman, D., Cencic, V., Letonja, M., Winkler, R., Valentincic, M., Melihen-Bartolic, C., Bartolic, A., Pusnik Vrckovnik, M., Kladnik, M., Slemenik Pusnik, C., Marolt, A., Klen, J., Drnovsek, B., Leskovar, B., Fernandez Anguita, M.J., Gallego Page, J.C., Salmeron Martinez, F.M., Andres, J., Genis, A.B., Mirabet, S., Mendez, A., Garcia-Cosio, L., Roig, E., Leon, V., Gonzalez-Costello, J., Muntane, G., Garay, A., Alcade-Martinez, V., Lopez Fernandez, S., Rivera-Lopez, R., Puga-Martinez, M., Fernandez-Alvarez, M., Serrano-Martinez, J.L., Grille-Cancela, Z., Marzoa-Rivas, R., Blanco-Canosa, P., Paniagua-Martin, M.J., Barge-Caballero, E., Laynez Cerdena, I., Famara Hernandez Baldomero, I., Lara Padron, A., Ofelia Rosillo, S., Dalmau Gonzalez-Gallarza, R., Salvador Montanes, O., Iniesta Manjavacas, A.M., Castro Conde, A., Araujo, A., Soria, T., Garcia-Pavia, P., Gomez-Bueno, M., Cobo-Marcos, M., Alonso-Pulpon, L., Segovia Cubero, J., Sayago, I., Gonzalez-Segovia, A., Briceno, A., Escribano Subias, P., Vicente Hernandez, M., Ruiz Cano, M.J., Gomez Sanchez, M.A., Barrios Garrido-Lestache, E., Garcia Pinilla, J.M., Garcia de la Villa, B., Sahuquillo, A., Bravo Marques, R., Torres Calvo, F., Perez-Martinez, M.T., Gracia-Rodenas, M.R., Garrido-Bravo, I.P., Pastor-Perez, F., Pascual-Figal, D.A., Diaz Molina, B., Orus, J., Epelde Gonzalo, F., Bertomeu, V., Valero, R., Martinez-Abellan, R., Quiles, J., Rodrigez-Ortega, J.A., Mateo, I., ElAmrani, A., Fernandez-Vivancos, C., Bierge Valero, D., Almenar-Bonet, L., Sanchez-Lazaro, I.J., Marques-Sule, E., Facila-Rubio, L., Perez-Silvestre, J., Garcia-Gonzalez, P., Ridocci-Soriano, F., Garcia-Escriva, D., Pellicer-Cabo, A., de la Fuente Galan, L., Lopez Diaz, J., Recio Platero, A., Arias, J.C., Blasco-Peiro, T., Sanz Julve, M., Sanchez-Insa, E., Aured-Guallar, C., Portoles-Ocampo, A., Melin, M., Hägglund, E., Stenberg, A., Lindahl, I.-M., Asserlund, B., Olsson, L., Afzelius, M., Karlström, P., Tengvall, L., Wiklund, P.-A., Olsson, B., Kalayci, S., Cavusoglu, Y., Gencer, E., Yilmaz, M.B., Gunes, H., Canepa, Marco, Fonseca, Candida, Chioncel, Ovidiu, Laroche, Cécile, Crespo-Leiro, Maria G., Coats, Andrew J.S., Mebazaa, Alexandre, Piepoli, Massimo F., Tavazzi, Luigi, and Maggioni, Aldo P.
- Published
- 2018
- Full Text
- View/download PDF
26. Influence of Apnea Hypopnea Index and the Degree of Airflow Limitation on Endothelial Function in Patients Undergoing Diagnostic Coronary Angiography
- Author
-
Dorota Ochijewicz, Adam Rdzanek, Tadeusz Przybyłowski, Renata Rubinsztajn, Monika Budnik, Ewa Pędzich, Katarzyna Białek-Gosk, Piotr Bielicki, and Agnieszka Kapłon-Cieślicka
- Subjects
obstructive sleep apnea ,endothelial dysfunction ,chronic coronary syndrome ,Biology (General) ,QH301-705.5 - Abstract
Background: Obstructive sleep apnea is associated with an increased prevalence of cardiovascular disease. The mechanism of these associations is not completely understood. We aimed to investigate the association of the apnea hypopnea index and the degree of airflow limitation with endothelial dysfunction. Methods: This was a single-center prospective study of patients admitted for diagnostic coronary angiography (CAG). Endothelial function was assessed by the non-invasive EndoPAT system by reactive hyperemia index (RHI) and divided into two groups: endothelial dysfunction and normal endothelial function. Sleep apnea signs were detected by WatchPAT measuring the respiratory disturbance index (pRDI), the apnea and hypopnea index (pAHI), and the oxygen desaturation index (ODI). Patients underwent spirometry and body plethysmography. Based on CAG, the severity of coronary artery disease was assessed as follows: no significant coronary artery disease, single-, two- and three-vessel disease. Results: A total of 113 patients were included in the study. Breathing disorders measured by WatchPAT and spirometry were more severe in patients with endothelial dysfunction: pRDI (27.3 vs. 14.8, p = 0.001), pAHI (24.6 vs. 10.3, p < 0.001), ODI (13.7 vs. 5.2, p = 0.002), forced expiratory volume in one second (FEV1) (81.2 vs. 89, p = 0.05). In a multivariate regression analysis, pAHI and FEV1 were independent predictors of endothelial dysfunction assessed by RHI. There was no correlation between the severity of coronary artery disease and endothelial dysfunction. Conclusions: Obstructive sleep apnea signs and greater airflow limitation were associated with endothelial dysfunction regardless of the severity of the coronary artery disease.
- Published
- 2022
- Full Text
- View/download PDF
27. Ischemic Cardiomyopathy versus Non-Ischemic Dilated Cardiomyopathy in Patients with Reduced Ejection Fraction— Clinical Characteristics and Prognosis Depending on Heart Failure Etiology (Data from European Society of Cardiology Heart Failure Registries)
- Author
-
Agata Tymińska, Krzysztof Ozierański, Paweł Balsam, Cezary Maciejewski, Anna Wancerz, Emil Brociek, Michał Marchel, Maria G. Crespo-Leiro, Aldo P. Maggioni, Jarosław Drożdż, Grzegorz Opolski, Marcin Grabowski, and Agnieszka Kapłon-Cieślicka
- Subjects
personalized management ,coronary artery disease ,atherosclerosis ,heart failure ,mortality ,Biology (General) ,QH301-705.5 - Abstract
Personalized management involving heart failure (HF) etiology is crucial for better prognoses for HF patients. This study aimed to compare patients with ischemic cardiomyopathy (ICM) and patients with non-ischemic dilated cardiomyopathy (NIDCM) in terms of baseline characteristics and prognosis. We assessed 895 patients with HF with reduced left ventricular ejection fraction participating in the Polish part of the European Society of Cardiology (ESC)-HF registries. ICM was present in 583 patients (65%), NIDCM in 312 patients (35%). The ICM patients were older (p < 0.001) and had more comorbidities. The NIDCM patients more frequently had atrial fibrillation (p = 0.04) and lower LVEF (p = 0.01); therefore, they were treated more often with anticoagulants (p = 0.01) and digitalis (p < 0.001). The NIDCM patients were prescribed aldosterone antagonists more often (p = 0.01). There were no other differences as regards the use of HF guideline-recommended medications, implantable cardioverter defibrillators or cardiac resynchronization therapy. The ICM patients were more likely to be treated with statins (p < 0.001) and antiplatelet agents (p < 0.001). All-cause death, as well as all-cause death and readmissions for HF at 12 months, occurred more often in the ICM group compared with the NIDCM group (15.9% vs. 10%, p = 0.016; and 40.9% vs. 28.6%, p = 0.00089, respectively). ICM etiology was an independent predictor of the composite endpoint in the total cohort (p = 0.003). The ICM patients were older and had more comorbidities, whereas the NIDCM patients had lower LVEF. One-year prognosis was worse in the ICM patients than in the NIDCM patients. ICM etiology was independently associated with a worse one-year outcome.
- Published
- 2022
- Full Text
- View/download PDF
28. Comparative Analysis of Long-Term Outcomes of Torasemide and Furosemide in Heart Failure Patients in Heart Failure Registries of the European Society of Cardiology
- Author
-
Ozierański, Krzysztof, Balsam, Paweł, Kapłon-Cieślicka, Agnieszka, Tymińska, Agata, Kowalik, Robert, Grabowski, Marcin, Peller, Michał, Wancerz, Anna, Marchel, Michał, Crespo-Leiro, Maria G., Maggioni, Aldo P., Drożdż, Jarosław, Filipiak, Krzysztof J., and Opolski, Grzegorz
- Published
- 2019
- Full Text
- View/download PDF
29. Rules for using reduced doses of non-vitamin K antagonist oral anticoagulants in the prevention of thromboembolic complications in patients with atrial fibrillation. The expert opinion of the Working Group on Cardiovascular Pharmacotherapy of the Polish Cardiac Society
- Author
-
Iwona Gorczyca-Głowacka, Agnieszka Kapłon-Cieślicka, Marcin Wełnicki, Filip Szymański, Marcin Barylski, Artur Mamcarz, Krzysztof J Filipiak, and Beata Wożakowska-Kapłon
- Subjects
Cardiology and Cardiovascular Medicine - Published
- 2022
30. Metabolic syndrome — a new definition and management guidelines
- Author
-
Piotr Dobrowolski, Aleksander Prejbisz, Alina Kuryłowicz, Alicja Baska, Paweł Burchardt, Krzysztof Chlebus, Grzegorz Dzida, Piotr Jankowski, Jerzy Jaroszewicz, Paweł Jaworski, Karol Kamiński, Agnieszka Kapłon-Cieślicka, Marek Klocek, Michał Kukla, Artur Mamcarz, Agnieszka Mastalerz-Migas, Krzysztof Narkiewicz, Lucyna Ostrowska, Daniel Śliż, Wiesław Tarnowski, Jacek Wolf, Mariusz Wyleżoł, Tomasz Zdrojewski, Maciej Banach, Andrzej Januszewicz, and Paweł Bogdański
- Subjects
Endocrinology, Diabetes and Metabolism ,Internal Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2022
31. COVID-19 associated atrial fibrillation: Incidence, putative mechanisms and potential clinical implications
- Author
-
Monika Gawałko, Agnieszka Kapłon-Cieślicka, Mathias Hohl, Dobromir Dobrev, and Dominik Linz
- Subjects
Anticoagulation ,Arrhythmia ,Inflammasome ,Remote monitoring ,Thromboembolic risk ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Coronavirus disease 2019 (COVID-19) is a novel, highly transmittable and severe strain disease, which has rapidly spread worldwide. Despite epidemiological evidence linking COVID-19 with cardiovascular diseases, little is known about whether and how COVID-19 influences atrial fibrillation (AF), the most prevalent arrhythmia in clinical practice. Here, we review the available evidence for prevalence and incidence of AF in patients infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and discuss disease management approaches and potential treatment options for COVID-19 infected AF patients.
- Published
- 2020
- Full Text
- View/download PDF
32. Left Ventricular Ejection Fraction Is Associated with the Risk of Thrombus in the Left Atrial Appendage in Patients with Atrial Fibrillation
- Author
-
Beata Uziębło-Życzkowska, Paweł Krzesiński, Agnieszka Jurek, Agnieszka Kapłon-Cieślicka, Iwona Gorczyca, Monika Budnik, Grzegorz Gielerak, Marek Kiliszek, Monika Gawałko, Piotr Scisło, Janusz Kochanowski, Olga Jelonek, Anna Michalska, Katarzyna Starzyk, Krzysztof J. Filipiak, Beata Wożakowska-Kapłon, and Grzegorz Opolski
- Subjects
Therapeutics. Pharmacology ,RM1-950 ,Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Introduction. Atrial fibrillation (AF) is associated with high risk of ischemic stroke. The most frequent thrombus location in AF is the left atrial appendage (LAA). Transthoracic echocardiography (TTE) is a basic diagnostic examination in patients (pts) with AF. Objectives. To analyse the relations between basic echocardiographic features, well-established stroke risk factors, type of AF, and anticoagulation therapy with the incidence of left atrial appendage thrombus (LAAT). Patients and Methods. The study group consisted of 768 pts with AF (mean age, 63 years), admitted to three high-reference cardiology departments. Five hundred and twenty-three pts were treated with non-vitamin K antagonist oral anticoagulants (NOACs) and 227 (30%) with vitamin K antagonists (VKAs). The subjects underwent TTE and transesophageal echocardiography (TEE) before cardioversion or ablation. Results. LAAT was significantly more frequent in pts with reduced left ventricular ejection fraction (LVEF): in 10.6% (7 pts) with LVEF50%. Compared to pts without LAAT, those with LAAT presented with lower LVEF and higher left atrial diameter (LAD). Multivariate logistic regression revealed the following variables as independent predictors of LAAT: previous bleeding, treatment with VKA, and LVEF. Conclusion. LAAT is related to lower LVEF and higher LAD. LVEF is one of the independent predictors of LAAT. Even in the case of adequate anticoagulant therapy, it might be prudent to consider TEE before cardioversion or ablation in patients with low LVEF and LA enlargement, especially in the coexistence of other thromboembolic risk factors.
- Published
- 2020
- Full Text
- View/download PDF
33. Left Atrial Appendage Thrombus Formation Despite Continuous Non-Vitamin K Antagonist Oral Anticoagulant Therapy in Atrial Fibrillation Patients Undergoing Electrical Cardioversion or Catheter Ablation: A Comparison of Dabigatran and Rivaroxaban
- Author
-
Iwona Gorczyca, Magdalena Chrapek, Olga Jelonek, Anna Michalska, Agnieszka Kapłon-Cieślicka, Beata Uziębło-Życzkowska, Monika Budnik, Monika Gawałko, Paweł Krzesiński, Agnieszka Jurek, Piotr Scisło, Janusz Kochanowski, Marek Kiliszek, Grzegorz Gielerak, Krzysztof J. Filipiak, Grzegorz Opolski, and Beata Wożakowska-Kapłon
- Subjects
Diseases of the circulatory (Cardiovascular) system ,RC666-701 - Abstract
Left atrial appendage thrombus (LAAT) may be detected by transesophageal echocardiography (TOE) in patients with atrial fibrillation (AF) despite continuous anticoagulation therapy. We examined the factors predisposing to LAAT in patients treated with the anticoagulants dabigatran and rivaroxaban. We retrospectively evaluated 1,256 AF patients from three centres who underwent TOE before electrical cardioversion (n = 611, 51.4%) or catheter ablation (n = 645, 48.6%) from January 2013 to December 2019 and had been on at least three weeks of continuous dabigatran (n = 603, 48%) or rivaroxaban (n = 653, 52%) therapy. Preprocedural TOE diagnosed LAAT in 51 patients (4.1%), including 30 patients (5%) treated with dabigatran and 21 patients (3.2%) treated with rivaroxaban (p=0.1145). In multivariate logistic regression, predictors of LAAT in patients treated with dabigatran were non-paroxysmal AF (vs. paroxysmal AF) (OR = 6.2, p=0.015), heart failure (OR = 3.22, p=0.003), and a eGFR
- Published
- 2020
- Full Text
- View/download PDF
34. Personalized Management of Myocarditis and Inflammatory Cardiomyopathy in Clinical Practice
- Author
-
Agata Tymińska, Krzysztof Ozierański, Aleksandra Skwarek, Agnieszka Kapłon-Cieślicka, Anna Baritussio, Marcin Grabowski, Renzo Marcolongo, and Alida LP Caforio
- Subjects
anti-heart autoantibodies ,endomyocardial biopsy ,heart failure ,individualized therapy ,inflammation ,immunosuppressive treatment ,Medicine - Abstract
Myocarditis is an inflammatory heart disease induced by infectious and non-infectious causes frequently triggering immune-mediated pathologic mechanisms leading to myocardial damage and dysfunction. In approximately half of the patients, acute myocarditis resolves spontaneously while in the remaining cases, it may evolve into serious complications including inflammatory cardiomyopathy, arrhythmias, death, or heart transplantation. Due to the large variability in clinical presentation, unpredictable course of the disease, and lack of established causative treatment, myocarditis represents a challenging diagnosis in modern cardiology. Moreover, an increase in the incidence of myocarditis and inflammatory cardiomyopathy has been observed in recent years. However, there is a growing potential of available non-invasive diagnostic methods (biomarkers, serum anti-heart autoantibodies (AHA), microRNAs, speckle tracking echocardiography, cardiac magnetic resonance T1 and T2 tissue mapping, positron emission tomography), which may refine the diagnostic workup and/or noninvasive follow-up. Personalized management should include the use of endomyocardial biopsy and AHA, which may allow the etiopathogenetic subsets of myocarditis (infectious, non-infectious, and/or immune-mediated) to be distinguished and implementation of disease-specific therapies. In this review, we summarize current knowledge on myocarditis and inflammatory cardiomyopathy, and outline some practical diagnostic, therapeutic, and follow-up algorithms to facilitate comprehensive individualized management of these patients.
- Published
- 2022
- Full Text
- View/download PDF
35. Artificial intelligence in detecting left atrial appendage thrombus by transthoracic echocardiography and clinical features: the Left Atrial Thrombus on Transoesophageal Echocardiography (LATTEE) registry
- Author
-
Pieszko, Konrad, primary, Hiczkiewicz, Jarosław, additional, Łojewska, Katarzyna, additional, Uziębło-Życzkowska, Beata, additional, Krzesiński, Paweł, additional, Gawałko, Monika, additional, Budnik, Monika, additional, Starzyk, Katarzyna, additional, Wożakowska-Kapłon, Beata, additional, Daniłowicz-Szymanowicz, Ludmiła, additional, Kaufmann, Damian, additional, Wójcik, Maciej, additional, Błaszczyk, Robert, additional, Mizia-Stec, Katarzyna, additional, Wybraniec, Maciej, additional, Kosmalska, Katarzyna, additional, Fijałkowski, Marcin, additional, Szymańska, Anna, additional, Dłużniewski, Mirosław, additional, Kucio, Michał, additional, Haberka, Maciej, additional, Kupczyńska, Karolina, additional, Michalski, Błażej, additional, Tomaszuk-Kazberuk, Anna, additional, Wilk-Śledziewska, Katarzyna, additional, Wachnicka-Truty, Renata, additional, Koziński, Marek, additional, Kwieciński, Jacek, additional, Wolny, Rafał, additional, Kowalik, Ewa, additional, Kolasa, Iga, additional, Jurek, Agnieszka, additional, Budzianowski, Jan, additional, Burchardt, Paweł, additional, Kapłon-Cieślicka, Agnieszka, additional, and Slomka, Piotr J, additional
- Published
- 2023
- Full Text
- View/download PDF
36. Znaczenie optymalnej dawki kwasu acetylosalicylowego w prewencji incydentów sercowo-naczyniowych
- Author
-
Ozierański, Krzysztof, primary and Kapłon-Cieślicka, Agnieszka, additional
- Published
- 2023
- Full Text
- View/download PDF
37. Niewłaściwe przepisywanie zredukowanej dawki NOAC w praktyce klinicznej — wyniki Polskiego Rejestru Migotania Przedsionków (POL-AF) u hospitalizowanych pacjentów
- Author
-
Jelonek, Olga Elżbieta, primary, Gorczyca-Głowacka, Iwona, additional, Uziębło-Życzkowska, Beata, additional, Maciorowska, Małgorzata, additional, Wójcik, Maciej, additional, Błaszczyk, Robert, additional, Kapłon-Cieślicka, Agnieszka, additional, Gawałko, Monika, additional, Budnik, Monika, additional, Rajtar-Salwa, Renata, additional, Tokarek, Tomasz, additional, Bil, Jacek, additional, Wojewódzki, Michał, additional, Szpotowicz, Anna, additional, Krzciuk, Małgorzata, additional, Bednarski, Janusz, additional, Bakuła-Ostalska, Elwira, additional, Tomaszuk-Kazberuk, Anna, additional, Szyszkowska, Anna, additional, Wełnicki, Marcin, additional, Mamcarz, Artur, additional, and Wożakowska-Kapłon, Beata, additional
- Published
- 2023
- Full Text
- View/download PDF
38. Pharmacotherapy of heart failure A.D. 2023. Expert opinion of Working Group on Cardiovascular Pharmacotherapy, Polish Cardiac Society
- Author
-
Kasprzak, Jarosław D, primary, Gorczyca-Głowacka, Iwona, additional, Sobczak-Kaleta, Maria, additional, Barylski, Marcin, additional, Drożdż, Jarosław, additional, Filipiak, Krzysztof J, additional, Kapłon-Cieślicka, Agnieszka, additional, Lelonek, Małgorzata, additional, Mamcarz, Artur, additional, Ochijewicz, Dorota, additional, Ryś-Czaporowska, Anna, additional, Starzyk, Katarzyna, additional, Szymański, Filip M, additional, Wełnicki, Marcin, additional, and Wożakowska-Kapłon, Beata, additional
- Published
- 2023
- Full Text
- View/download PDF
39. Out-of-hospital cardiac arrest: Do we have to perform coronary angiography?
- Author
-
Wańha, Wojciech, primary, Kołodziejczak, Michalina, additional, Kowalewski, Mariusz, additional, Januszek, Rafał, additional, Kuźma, Łukasz, additional, Jaguszewski, Miłosz, additional, Tomaniak, Mariusz, additional, Darocha, Szymon, additional, Kupczyńska, Karolina, additional, Dobrowolski, Piotr, additional, Tymińska, Agata, additional, Ciepłucha, Aleksandra, additional, Sokolska, Justyna, additional, Kapłon-Cieślicka, Agnieszka, additional, Kułach, Andrzej, additional, Wybraniec, Maciej, additional, Roleder, Tomasz, additional, Tajstra, Mateusz, additional, Nadolny, Klaudiusz, additional, Darocha, Tomasz, additional, Sierakowska, Katarzyna, additional, Pawłowski, Tomasz, additional, Gierlotka, Marek, additional, Leskiak, Maciej, additional, Wita, Krystian, additional, Gil, Robert, additional, and Trzeciak, Przemysław, additional
- Published
- 2023
- Full Text
- View/download PDF
40. Anemia at Hospital Admission and Its Relation to Outcomes in Patients With Heart Failure (from the Polish Cohort of 2 European Society of Cardiology Heart Failure Registries)
- Author
-
Tymińska, Agata, Kapłon-Cieślicka, Agnieszka, Ozierański, Krzysztof, Peller, Michał, Balsam, Paweł, Marchel, Michał, Crespo-Leiro, Maria G., Maggioni, Aldo P., Jankowska, Ewa A., Drożdż, Jarosław, Filipiak, Krzysztof J., and Opolski, Grzegorz
- Published
- 2017
- Full Text
- View/download PDF
41. Oral anticoagulation therapy in atrial fibrillation patients at high risk of bleeding: Clinical characteristics and treatment strategies based on data from the Polish multicenter register of atrial fibrillation (POL-AF).
- Author
-
Maciorowska, Małgorzata, Uziębło-Życzkowska, Beata, Gorczyca-Głowacka, Iwona, Wożakowska-Kapłon, Beata, Jelonek, Olga, Wójcik, Maciej, Błaszczyk, Robert, Kapłon-Cieślicka, Agnieszka, Gawałko, Monika, Tokarek, Tomasz, Rajtar-Salwa, Renata, Bil, Jacek, Wojewódzki, Michał, Szpotowicz, Anna, Krzciuk, Małgorzata, Bednarski, Janusz, Bakuła-Ostalska, Elwira, Tomaszuk-Kazberuk, Anna, Szyszkowska, Anna, and Wełnicki, Marcin
- Published
- 2024
- Full Text
- View/download PDF
42. Position paper of the Polish Expert Group on the use of pitavastatin in the treatment of lipid disorders in Poland endorsed by the Polish Lipid Association.
- Author
-
Banach, Maciej, Surma, Stanisław, Kapłon-Cieślicka, Agnieszka, Mitkowski, Przemysław, Dzida, Grzegorz, Tomasik, Tomasz, and Mastalerz-Migas, Agnieszka
- Subjects
PITAVASTATIN ,DYSLIPIDEMIA ,LDL cholesterol ,LIPIDS ,ANTILIPEMIC agents - Abstract
Lipid disorders, primarily hypercholesterolemia, are the most common cardiovascular (CV) risk factor in Poland (this applies even 3/4 of people). The low-density lipoprotein cholesterol (LDL-C) serum level is the basic lipid parameter that should be measured to determine CV risk and determines the aim and target of lipid-lowering treatment (LLT). Lipid-lowering treatment improves cardiovascular prognosis and prolongs life in both primary and secondary cardiovascular prevention. Despite the availability of effective lipid-lowering drugs and solid data on their beneficial effects, the level of LDL-C control is highly insufficient. This is related, among other things, to physician inertia and patients' fear of side effects. The development of lipidology has made drugs available with a good safety profile and enabling personalisation of therapy. Pitavastatin, the third most potent lipid-lowering statin, is characterised by a lower risk of muscle complications and new cases of diabetes due to its being metabolised differently. Thus, pitavastatin is a very good therapeutic option in patients at high risk of diabetes or with existing diabetes, and in patients at cardiovascular risk. This expert opinion paper attempts at recommendation on the place and possibility of using pitavastatin in the treatment of lipid disorders. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. Why Did All Patients with Atrial Fibrillation and High Risk of Stroke Not Receive Oral Anticoagulants? Results of the Polish Atrial Fibrillation (POL-AF) Registry
- Author
-
Anna Szpotowicz, Iwona Gorczyca, Olga Jelonek, Beata Uziębło-Życzkowska, Małgorzata Maciorowska, Maciej Wójcik, Robert Błaszczyk, Agnieszka Kapłon-Cieślicka, Monika Gawałko, Monika Budnik, Tomasz Tokarek, Renata Rajtar-Salwa, Jacek Bil, Michał Wojewódzki, Janusz Bednarski, Elwira Bakuła-Ostalska, Anna Tomaszuk-Kazberuk, Anna Szyszkowska, Marcin Wełnicki, Artur Mamcarz, Małgorzata Krzciuk, and Beata Wożakowska-Kapłon
- Subjects
atrial fibrillation ,non-vitamin K antagonist oral anticoagulants ,oral anticoagulants ,stroke risk ,vitamin K antagonists ,Medicine - Abstract
Background: Most atrial fibrillation (AF) patients are at high risk of thromboembolic, and the use of oral anticoagulants (OACs) is advised in such cases. The aim of the study was to evaluate the frequency at which OACs were used in patients with AF and high risk thromboembolic complications, and identify factors that result in OACs not being used in the researched group of patients. Methods: The prospective, multicenter and non-interventional POL-AF registry is a study that includes AF patients from ten Polish cardiology centers. They were consecutively hospitalized between January and December of 2019. All the patients in the study were of high stroke risk. Results: A total of 3614 patients with AF and high stroke risk were included. Among the total study population, 91.5% received OAC therapy; antiplatelet therapy was prescribed for 3.7% of patients, heparin for 2.7%, and 2.1% of patients did not receive any stroke prevention therapy. Independent predictors of no OAC prescription were intracranial bleeding (OR 0.15, 95%CI 0.07–0.35, p < 0.001), gastrointestinal bleeding (OR 0.25, 95%CI 0.17–0.37, p < 0.001), cancer (OR 0.37, 95%CI 0.25–0.55, p < 0.001), hospitalization due to acute coronary syndrome (OR 0.48, 95%CI 0.33–0.69, p < 0.001), and anemia (OR 0.62, 95%CI 0.48–0.81, p < 0.001). Conclusions: Most AF patients with a high thromboembolic risk received OACs. The factors predisposing a lack of OAC use in these patients were conditions that significantly increased the risk of bleeding complications.
- Published
- 2021
- Full Text
- View/download PDF
44. Stanowisko grupy polskich ekspertów na temat stosowania pitawastatyny w leczeniu zaburzeń lipidowych w Polsce pod patronatem Polskiego Towarzystwa Lipidologicznego.
- Author
-
Banach, Maciej, Surma, Stanisław, Kapłon-Cieślicka, Agnieszka, Mitkowski, Przemysław, Dzida, Grzegorz, Tomasik, Tomasz, and Mastalerz-Migas, Agnieszka
- Abstract
Copyright of General Practitioner / Lekarz POZ is the property of Termedia Publishing House and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2023
45. Risk of left atrial appendage thrombus in older patients with atrial fibrillation.
- Author
-
Gawałko, Monika, Budnik, Monika, Uziębło-Życzkowska, Beata, Gorczyca, Iwona, Krzesiński, Paweł, Scisło, Piotr, Kochanowski, Janusz, Michalska, Anna, Jelonek, Olga, Starzyk, Katarzyna, Jurek, Agnieszka, Kiliszek, Marek, Wożakowska-Kapłon, Beata, Gielerak, Grzegorz, Filipiak, Krzysztof J., Opolski, Grzegorz, and Kapłon-Cieślicka, Agnieszka
- Subjects
OLDER patients ,LEFT heart atrium ,ATRIAL fibrillation ,THROMBOSIS ,ANTICOAGULANTS - Abstract
Introduction: We aimed to compare the prevalence of left atrial appendage (LAA) thrombus and its predictors between old and young patients with atrial fibrillation (AF). Material and methods: The study included 1970 patients aged = 65 (n = 822 (41.7%)) and < 65 (n = 1148 (58.3%)) referred for AF cardioversion or ablation preceded by transoesophageal echocardiography (TEE). Results: Oral anticoagulation (OAC) was prescribed in 799 (97.2%) patients aged = 65 years and in 1054 (91.8%) of those aged < 65 years (p < 0.001). In patients treated with OAC, those aged = 65 years less often received vitamin K antagonist (VKA) (267 (33.4%) vs. 416 (39.5%)) and more often non-VKA-OAC (NOAC) (532 (66.6%) vs. 638 (60.5%), p = 0.008, p = 0.008) compared to patients < 65 years. On TEE, LAA thrombus was more often observed in patients aged = 65 years than those aged < 65 years (63 (7.7%) vs. 46 (4.0%), p < 0.001), with an absolute but not statistically significant difference between patients aged 65-74 and = 75 years (47 (7.3%) vs. 16 (8.8%), p = 0.528). In patients aged = 65 years, there was no difference in the prevalence of LAA thrombus between patients treated with VKA and NOAC, in contrast to patients aged < 65 years, in whom such a difference was observed (27 (6.5%) vs. 16 (2.5%), p = 0.002). In multivariate logistic regression, predictors of LAA thrombus in both age groups were older age, non-paroxysmal AF, and heart failure, whereas only in patients aged < 65 years - VKA use, and in those aged = 65 years - lower glomerular filtration rate and platelet count. Conclusions: Despite OAC use, older patients with AF remain at high risk of LAA thrombus formation. Older age, non-paroxysmal AF, and heart failure are predictors of LAA thrombus, irrespective of age. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
46. Does the CHA2DS2-VASc scale sufficiently predict the risk of left atrial appendage thrombus in patients with diagnosed atrial fibrillation treated with non-vitamin K oral anticoagulants?
- Author
-
Michalska, Anna, Gorczyca, Iwona, Chrapek, Magdalena, Kapłon-Cieślicka, Agnieszka, Uziębło-Życzkowska, Beata, Starzyk, Katarzyna, Jelonek, Olga, Budnik, Monika, Gawałko, Monika, Krzesiński, Paweł, Jurek, Agnieszka, Scisło, Piotr, Kochanowski, Janusz, Kiliszek, Marek, Gielerak, Grzegorz, Filipiak, Krzysztof J., Opolski, Grzegorz, and Wożakowska-Kapłon, Beata
- Published
- 2020
- Full Text
- View/download PDF
47. Out-of-hospital cardiac arrest: Do we have to perform coronary angiography?
- Author
-
Wojciech Wańha, Michalina Kołodziejczak, Mariusz Kowalewski, Rafał Januszek, Łukasz Kuźma, Miłosz Jaguszewski, Mariusz Tomaniak, Szymon Darocha, Karolina Kupczyńska, Piotr Dobrowolski, Agata Tymińska, Aleksandra Ciepłucha, Justyna Sokolska, Agnieszka Kapłon-Cieślicka, Andrzej Kułach, Maciej Wybraniec, Tomasz Roleder, Mateusz Tajstra, Klaudiusz Nadolny, Tomasz Darocha, Katarzyna Sierakowska, Tomasz Pawłowski, Marek Gierlotka, Maciej Leskiak, Krystian Wita, Robert Gil, and Przemysław Trzeciak
- Subjects
General Medicine ,Cardiology and Cardiovascular Medicine - Published
- 2023
48. Left Ventricular Outflow Tract Obstruction Due to Elongation of Anterior Mitral Leaflet: A Role for Exercise Testing?
- Author
-
Kapłon-Cieślicka, Agnieszka, Piotrowska-Kownacka, Dorota, Marchel, Michał, Gawałko, Monika, and Kochanowski, Janusz
- Published
- 2019
- Full Text
- View/download PDF
49. Hyponatraemia and changes in natraemia during hospitalization for acute heart failure and associations with in-hospital and long-term outcomes - from the ESC-HFA EORP Heart Failure Long-Term Registry
- Author
-
Kapłon-Cieślicka, Agnieszka, Benson, Lina, Chioncel, Ovidiu, Crespo-Leiro, Maria G, Coats, Andrew J S, Anker, Stefan D, Ruschitzka, Frank; https://orcid.org/0000-0001-5972-0596, Hage, Camilla, Drożdż, Jarosław, Seferovic, Petar, Rosano, Giuseppe M C, Piepoli, Massimo, Mebazaa, Alexandre, McDonagh, Theresa, Lainscak, Mitja, Savarese, Gianluigi, Ferrari, Roberto, Mullens, Wilfried, Bayes-Genis, Antoni, Maggioni, Aldo P, Lund, Lars H; https://orcid.org/0000-0003-1411-4482, Kapłon-Cieślicka, Agnieszka, Benson, Lina, Chioncel, Ovidiu, Crespo-Leiro, Maria G, Coats, Andrew J S, Anker, Stefan D, Ruschitzka, Frank; https://orcid.org/0000-0001-5972-0596, Hage, Camilla, Drożdż, Jarosław, Seferovic, Petar, Rosano, Giuseppe M C, Piepoli, Massimo, Mebazaa, Alexandre, McDonagh, Theresa, Lainscak, Mitja, Savarese, Gianluigi, Ferrari, Roberto, Mullens, Wilfried, Bayes-Genis, Antoni, Maggioni, Aldo P, and Lund, Lars H; https://orcid.org/0000-0003-1411-4482
- Abstract
AIMS: To comprehensively assess hyponatraemia in acute heart failure (AHF) regarding prevalence, associations, hospital course, and post-discharge outcomes. METHODS AND RESULTS: Of 8298 patients in the European Society of Cardiology Heart Failure Long-Term Registry hospitalized for AHF with any ejection fraction, 20% presented with hyponatraemia (serum sodium <135 mmol/L). Independent predictors included lower systolic blood pressure, estimated glomerular filtration rate (eGFR) and haemoglobin, along with diabetes, hepatic disease, use of thiazide diuretics, mineralocorticoid receptor antagonists, digoxin, higher doses of loop diuretics, and non-use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and beta-blockers. In-hospital death occurred in 3.3%. The prevalence of hyponatraemia and in-hospital mortality with different combinations were: 9% hyponatraemia both at admission and discharge (hyponatraemia Yes/Yes, in-hospital mortality 6.9%), 11% Yes/No (in-hospital mortality 4.9%), 8% No/Yes (in-hospital mortality 4.7%), and 72% No/No (in-hospital mortality 2.4%). Correction of hyponatraemia was associated with improvement in eGFR. In-hospital development of hyponatraemia was associated with greater diuretic use and worsening eGFR but also more effective decongestion. Among hospital survivors, 12-month mortality was 19% and adjusted hazard ratios (95% confidence intervals) were for hyponatraemia Yes/Yes 1.60 (1.35-1.89), Yes/No 1.35 (1.14-1.59), and No/Yes 1.18 (0.96-1.45). For death or heart failure hospitalization they were 1.38 (1.21-1.58), 1.17 (1.02-1.33), and 1.09 (0.93-1.27), respectively. CONCLUSION: Among patients with AHF, 20% had hyponatraemia at admission, which was associated with more advanced heart failure and normalized in half of patients during hospitalization. Admission hyponatraemia (possibly dilutional), especially if it did not resolve, was associated with worse in-hospital and post-discharge outcomes. Hyponatraemia dev
- Published
- 2023
50. Diagnosis, Clinical Course, and 1-Year Outcome in Patients Hospitalized for Heart Failure With Preserved Ejection Fraction (from the Polish Cohort of the European Society of Cardiology Heart Failure Long-Term Registry)
- Author
-
Kapłon-Cieślicka, Agnieszka, Tymińska, Agata, Peller, Michał, Balsam, Paweł, Ozierański, Krzysztof, Galas, Michalina, Marchel, Michał, Crespo-Leiro, Maria G., Maggioni, Aldo Pietro, Drożdż, Jarosław, Filipiak, Krzysztof J., and Opolski, Grzegorz
- Published
- 2016
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.